2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: AZ

Poster-Symptom Management

October 25, 2021

Symptom Burden and Treatment Goals of People with MS Spasticity: Results from SEEN-MSS, a Large-Scale, Self-Reported Survey

Background: Evidence suggests that people with multiple sclerosis and spasticity (pwMSS) experience multiple concurrent symptoms that...

Read More →

Poster-Quality of Life and Outcomes

October 25, 2021

Assessing Presence of MS-Related Symptoms As a Proxy for Disease Severity in Multiple Sclerosis Using Administrative Claims Data

Background: Healthcare claims data lack clinically relevant variables such as disease severity. Objectives: Assess multiple sclerosis...

Read More →

Poster-Quality of Life and Outcomes

October 25, 2021

Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis

Background: Historically, there has been limited research on care partners of patients with multiple sclerosis (MS). Employers, health care...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls

Background: Early intervention with high efficacy therapies has been shown to reduce long-term disability accrual in patients with multiple...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Long-Term Efficacy and Safety of Eculizumab Monotherapy in AQP4+ Neuromyelitis Optica Spectrum Disorder

Background: In the randomized, double-blind, placebo-controlled, phase 3 PREVENT trial (NCT01892345), eculizumab was well tolerated and...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety of Eculizumab in Nmosd and MG – Analysis of the Phase 3 Studies Prevent and Regain and Their Extensions

Background: Aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD) and acetylcholine receptor...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from Prevent

Background: In PREVENT, eculizumab was associated with a significant reduction in relapse risk versus placebo and was well tolerated. In...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Psoriasis in Multiple Sclerosis Patients Treated with Disease Modifying Therapies

Background: Psoriasis may be more common in people living with multiple sclerosis (PwMS) than in the general population. Some pathways...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Long-Term Efficacy and Safety of Eculizumab in AQP4+ Neuromyelitis Optica Spectrum Disorder

Background: Neuromyelitis optica spectrum disorder (NMOSD) relapses can cause significant and irreversible neurologic disability. In...

Read More →

Platform-Psychosocial

October 25, 2021

The Art of the Patient Conversation: Advanced Practice Provider Perspectives to Improve Outcomes in Multiple Sclerosis

Background: Robust health literacy, defined by the Centers for Disease Control and Prevention as the degree to which an individual can...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC